disulfiram has been researched along with Carcinoma, Non-Small Cell Lung in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 5.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| "Disulfiram is an inexpensive and safe drug; if its addition to chemotherapy could be shown to prolong survival, an effective regimen could be established and used widely, even in resource-poor countries." | 2.80 | A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. ( Baron, A; Gotfried, M; Hamamreh, Y; Nechushtan, H; Nidal, S; Nisman, B; Peretz, T; Peylan-Ramu, N; Shalev, YI, 2015) |
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 1.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kryczka, J | 2 |
| Janczewski, Ł | 1 |
| Gajda, A | 1 |
| Frączyk, A | 1 |
| Boncela, J | 1 |
| Kolesińska, B | 1 |
| Brzeziańska-Lasota, E | 1 |
| Yuan, XX | 1 |
| Duan, YF | 1 |
| Luo, C | 1 |
| Li, L | 1 |
| Yang, MJ | 1 |
| Liu, TY | 1 |
| Cao, ZR | 1 |
| Huang, W | 1 |
| Bu, X | 1 |
| Yue, X | 1 |
| Liu, RY | 1 |
| Bagherpoor, AJ | 1 |
| Shameem, M | 1 |
| Luo, X | 1 |
| Seelig, D | 1 |
| Kassie, F | 1 |
| Wang, N | 2 |
| Zhu, D | 1 |
| Liu, Y | 2 |
| Wu, J | 1 |
| Wang, M | 1 |
| Jin, S | 1 |
| Fu, F | 1 |
| Li, B | 1 |
| Ji, H | 1 |
| Du, C | 1 |
| Zheng, Z | 1 |
| Wang, NN | 1 |
| Wang, LH | 1 |
| Li, Y | 2 |
| Fu, SY | 1 |
| Xue, X | 2 |
| Jia, LN | 1 |
| Yuan, XZ | 1 |
| Wang, YT | 1 |
| Tang, X | 1 |
| Yang, JY | 1 |
| Wu, CF | 1 |
| Bucci, M | 1 |
| Wu, X | 1 |
| Wang, L | 2 |
| Wang, W | 2 |
| Han, J | 1 |
| Sun, X | 1 |
| Zhang, H | 1 |
| Che, X | 1 |
| Yang, J | 3 |
| Wu, C | 2 |
| Chen, X | 1 |
| Yang, Q | 1 |
| Chen, J | 2 |
| Zhang, P | 1 |
| Huang, Q | 1 |
| Zhang, X | 2 |
| Yang, L | 1 |
| Xu, D | 1 |
| Zhao, C | 1 |
| Wang, X | 1 |
| Liu, J | 1 |
| Duan, L | 1 |
| Shen, H | 1 |
| Zhao, G | 1 |
| Yang, R | 1 |
| Cai, X | 1 |
| Zhang, L | 1 |
| Jin, C | 1 |
| Huang, Y | 1 |
| Nechushtan, H | 1 |
| Hamamreh, Y | 1 |
| Nidal, S | 1 |
| Gotfried, M | 1 |
| Baron, A | 1 |
| Shalev, YI | 1 |
| Nisman, B | 1 |
| Peretz, T | 1 |
| Peylan-Ramu, N | 1 |
| Liu, X | 1 |
| Cui, W | 1 |
| Yuan, X | 1 |
| Lin, L | 1 |
| Cao, Q | 1 |
| Guo, W | 1 |
| Najlah, M | 1 |
| Ahmed, Z | 1 |
| Iqbal, M | 1 |
| Wang, Z | 1 |
| Tawari, P | 1 |
| McConville, C | 1 |
| Wang, C | 1 |
| Han, H | 1 |
| Wang, Y | 2 |
| Li, Q | 1 |
| O'Brien, A | 1 |
| Barber, JE | 1 |
| Reid, S | 1 |
| Niknejad, N | 1 |
| Dimitroulakos, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine[NCT00312819] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for disulfiram and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-F | 2015 |
13 other studies available for disulfiram and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Isothiocyanates (ITCs) 1-(Isothiocyanatomethyl)-4-phenylbenzene and 1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene-Aldehyde Dehydrogenase (ALDH) Inhibitors, Decreases Cisplatin Tolerance and Migratory Ability of NSCLC.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Benzene; Carcinoma, Non-Small-Cell Lung; Cell Line, T | 2022 |
Disulfiram enhances cisplatin cytotoxicity by forming a novel platinum chelate Pt(DDTC)
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation | 2023 |
Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung | 2023 |
NPLOC4 is a potential target and a poor prognostic signature in lung squamous cell carcinoma.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disulfiram; Humans; Lung; Lung Neoplasms; | 2023 |
Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
Topics: A549 Cells; Aldehyde Dehydrogenase, Mitochondrial; Animals; Carcinoma, Non-Small-Cell Lung; Cell Lin | 2018 |
Cancer therapy: A path of DSF destruction.
Topics: Carcinoma, Non-Small-Cell Lung; Disulfiram; Humans; Illicit Drugs; Lung Neoplasms | 2018 |
Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tum | 2018 |
Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumo | 2018 |
Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cel | 2014 |
Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Carcinoma, Non-Small-Cell Lung; Ce | 2016 |
Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disulfiram; Humans; Lactic Acid; Lung Neoplasms; M | 2017 |
Disulfiram-loaded porous PLGA microparticle for inhibiting the proliferation and migration of non-small-cell lung cancer.
Topics: Administration, Inhalation; Alcohol Deterrents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; C | 2017 |
Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |